Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Bone

Osteoporosis therapy—time to consider renal function

Nature Reviews Endocrinology volume 7, pages 440–441 (2011)Cite this article

Subjects

Treatment options for osteoporosis are limited for older individuals with chronic kidney disease. A secondary analysis of the FREEDOM trial sheds light on the efficacy and safety of denosumab in patients with impaired kidney function, but underlines that challenges remain in the treatment of osteoporosis in patients with severe chronic kidney disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jamal, S. et al. The effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Miner. Res. doi:10.1002/jbmr.403.

  2. Jamal, S. A. et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. J. Bone Miner. Res. 22, 503–508 (2007).

    Article  CAS  Google Scholar 

  3. Miller, P. D. et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J. Bone Miner. Res. 20, 2105–2115 (2005).

    Article  CAS  Google Scholar 

  4. Ishani, A., et al. The effect of raloxifene treatment in postmenopausal women with CKD. J. Am. Soc. Nephrol. 19, 1430–1438 (2008).

    Article  CAS  Google Scholar 

  5. Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A. & Krege, J. H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos. Int. 18, 59–68 (2007).

    Article  CAS  Google Scholar 

  6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. 76 (Suppl. 113) S1–S130 (2009).

  7. Gómez-Alonso, C. et al. Vitamin D status and secondary hyperparathyroidism: the importance of 25-hydroxyvitamin D cut-off levels. Kidney Int. 63 (Suppl. 85) S44–S48 (2003).

    Article  Google Scholar 

  8. Levin, A. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71, 31–38 (2007).

    Article  CAS  Google Scholar 

  9. Block, J. et al. A single dose study of denosumab in patients with various degrees of renal impairment [abstract]. Page 6. In National Kidney Foundation 2010 Spring Clinical Meeting Abstracts. http://www.kidney.org/news/meetings/clinical/pdf/CM10_abstracts.pdf.

Download references

Author information

Authors and Affiliations

  1. Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación, REDinREN del ISCIII, Hospital Universitario Central de Asturias, C/ Julián Clavería, s/n 33006, Oviedo, Spain

    Jorge B. Cannata-Andía & Carlos Gómez-Alonso

Authors
  1. Jorge B. Cannata-Andía
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlos Gómez-Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jorge B. Cannata-Andía.

Ethics declarations

Competing interests

J. B. Cannata-Andía declares association (grant/research support) with the following companies: Abbott, Amgen, Servier, Shire. C. Gómez-Alonso declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cannata-Andía, J., Gómez-Alonso, C. Osteoporosis therapy—time to consider renal function. Nat Rev Endocrinol 7, 440–441 (2011). https://doi.org/10.1038/nrendo.2011.114

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2011.114

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing